Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.

Autor:	Roeper, Julia, Kurz, Sylke, Grohé, Christian, Griesinger, Frank
Předmět:	THERAPEUTIC use of antineoplastic agents LUNG cancer GENETIC mutation PROTEIN kinase inhibitors LUNG tumors CELL receptors METASTASIS DRUG resistance in cancer cells
Zdroj:	Future Oncology; Feb2021, Vol. 17 Issue 4, p471-486, 15p
Abstrakt:	Clinical trial and real-world data in non-small-cell lung cancer indicate that 10-60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu